Metoclopramide (Intranasal)

In adults with functional dyspepsia, metoclopramide nasal spray provided symptomatic improvement comparable to oral metoclopramide, including reductions in upper abdominal discomfort and early satiety. The intranasal route was well tolerated and associated mainly with mild nasal irritation and dysgeusia.

In adults with diabetic gastroparesis, intranasal metoclopramide 10 or 14 mg four times daily improved overall gastroparesis symptom scores compared with baseline, with statistically significant benefits observed in women but not in men relative to placebo. The most common adverse events were dysgeusia, headache, and fatigue, and overall tolerability was favorable.

In adults with functional dyspepsia, metoclopramide nasal spray provided symptomatic improvement comparable to oral metoclopramide, including reductions in upper abdominal discomfort and early satiety. The intranasal route was well tolerated and associated mainly with mild nasal irritation and dysgeusia.

In adults with diabetic gastroparesis, intranasal metoclopramide 10 or 14 mg four times daily improved overall gastroparesis symptom scores compared with baseline, with statistically significant benefits observed in women but not in men relative to placebo. The most common adverse events were dysgeusia, headache, and fatigue, and overall tolerability was favorable.

In laparoscopic surgery patients receiving intranasal metoclopramide 20 mg for prophylaxis, the incidence of postoperative nausea and vomiting was not significantly reduced compared with placebo, suggesting limited efficacy of this specific intranasal dose and regimen in this setting. Tolerability was acceptable, with minor nasal irritation and unpleasant taste reported.

Across several small trials in cancer patients, intranasal metoclopramide at doses up to 80 mg reduced the frequency of acute vomiting associated with highly emetogenic chemotherapy and showed comparable efficacy to intramuscular or oral metoclopramide for moderately emetogenic regimens. Nasal administration was generally well tolerated, with minor nasal irritation and unpleasant taste being the main adverse effects.

In laparoscopic surgery patients receiving intranasal metoclopramide 20 mg for prophylaxis, the incidence of postoperative nausea and vomiting was not significantly reduced compared with placebo, suggesting limited efficacy of this specific intranasal dose and regimen in this setting. Tolerability was acceptable, with minor nasal irritation and unpleasant taste reported.

Across several small trials in cancer patients, intranasal metoclopramide at doses up to 80 mg reduced the frequency of acute vomiting associated with highly emetogenic chemotherapy and showed comparable efficacy to intramuscular or oral metoclopramide for moderately emetogenic regimens. Nasal administration was generally well tolerated, with minor nasal irritation and unpleasant taste being the main adverse effects.

In adults with functional dyspepsia, metoclopramide nasal spray provided symptomatic improvement comparable to oral metoclopramide, including reductions in upper abdominal discomfort and early satiety. The intranasal route was well tolerated and associated mainly with mild nasal irritation and dysgeusia.

In a crossover study of healthy men and women, single intranasal doses of metoclopramide (15–17 mg) produced systemic exposure comparable to a 10 mg oral tablet, with less interindividual variability and no unexpected safety signals. Common adverse events included headache, fatigue, and dysgeusia, which were generally mild and transient.

Across several small trials in cancer patients, intranasal metoclopramide at doses up to 80 mg reduced the frequency of acute vomiting associated with highly emetogenic chemotherapy and showed comparable efficacy to intramuscular or oral metoclopramide for moderately emetogenic regimens. Nasal administration was generally well tolerated, with minor nasal irritation and unpleasant taste being the main adverse effects.

In a crossover study of healthy men and women, single intranasal doses of metoclopramide (15–17 mg) produced systemic exposure comparable to a 10 mg oral tablet, with less interindividual variability and no unexpected safety signals. Common adverse events included headache, fatigue, and dysgeusia, which were generally mild and transient.

In adults with diabetic gastroparesis, intranasal metoclopramide 10 or 14 mg four times daily improved overall gastroparesis symptom scores compared with baseline, with statistically significant benefits observed in women but not in men relative to placebo. The most common adverse events were dysgeusia, headache, and fatigue, and overall tolerability was favorable.

In a crossover study of healthy men and women, single intranasal doses of metoclopramide (15–17 mg) produced systemic exposure comparable to a 10 mg oral tablet, with less interindividual variability and no unexpected safety signals. Common adverse events included headache, fatigue, and dysgeusia, which were generally mild and transient.

In adults with diabetic gastroparesis, intranasal metoclopramide 10 or 14 mg four times daily improved overall gastroparesis symptom scores compared with baseline, with statistically significant benefits observed in women but not in men relative to placebo. The most common adverse events were dysgeusia, headache, and fatigue, and overall tolerability was favorable.

In a crossover study of healthy men and women, single intranasal doses of metoclopramide (15–17 mg) produced systemic exposure comparable to a 10 mg oral tablet, with less interindividual variability and no unexpected safety signals. Common adverse events included headache, fatigue, and dysgeusia, which were generally mild and transient.

In healthy adult volunteers, a single 5 mg intranasal dose of metoclopramide produced measurable plasma concentrations with an absolute bioavailability of about 50% relative to oral administration, and peak levels were reached somewhat later than with intramuscular dosing. The study showed that intranasal administration achieves systemic exposure comparable to oral metoclopramide, supporting its use as an alternative route when oral absorption is unreliable.